Cited by 271Renal cell carcinoma treatmentCancer, Hypoxia, and MetabolismHepatocellular Carcinoma Treatment and Prognosis

The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.

Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET

Open access

Rankin, Erinn B., Fuh, Katherine C., Castellini, Laura, Viswanathan, Kartik, Finger, Elizabeth C., Diep, Anh N., LaGory, Edward L., Kariolis, Mihalis S., Chan, Andy, Lindgren, David, Axelson, Håkan, Miao, Yu R., Krieg, Adam J., Giaccia, Amato J.·2014·Proceedings of the National Academy of Sciences

DOI 10.1073/pnas.1404848111PMC PMC4169907

Open this paper in CoChat — free account Open PDF

Abstract

Significance: Here we report a fundamental and previously unknown role for the receptor tyrosine kinase AXL as a direct hypoxia-inducible transcription factor target driving the aggressive phenotype in renal clear cell carcinoma through the regulation of the SRC proto-oncogene nonreceptor tyrosine kinase and the MET proto-oncogene receptor tyrosine kinase. Of therapeutic relevance, we demonstrate that inactivation of growth arrest-specific 6 (GAS6)/AXL signaling using a soluble AXL decoy receptor reversed the invasive and metastatic phenotype of clear cell renal cell carcinoma (ccRCC) cells. Furthermore, we define a pathway by which GAS6/AXL signaling utilizes lateral activation of MET through SRC to maximize cellular invasion. Our data provide an alternative model for SRC and MET activation by GAS6 in ccRCC and identify AXL as a therapeutic target driving the aggressive phenotype in renal clear cell carcinoma.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1073/pnas.1404848111

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160
Targeting of HIF-α to the von Hippel-Lindau Ubiquitylation Complex by O 2 -Regulated Prolyl Hydroxylation
Jaakkola, P., Mole, D. R., Tian, Y.-M., Wilson, M. I., Gielbert, J., Gaskell, S. J., Kriegsheim, A. V., Hebestreit, H. F., Mukherji, M., Schofield, C. J., et al. (2001) · Science · doi:10.1126/science.1059796 · Cited by 5,535
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180
HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O 2 Sensing
Ivan, M., Kondo, K., Yang, H., Kim, W., Valiando, J., Ohh, M., Salic, A., Asara, J. M., Lane, W. S., & Kaelin Jr., W. G. (2001) · Science · doi:10.1126/science.1059817 · Cited by 4,735
Hypoxia-inducible factors in physiology and medicine
Semenza, G. L. (2012) · Cell · doi:10.1016/j.cell.2012.01.021 · Cited by 3,645
Identification of the von Hippel-Lindau Disease Tumor Suppressor Gene
Latif, F., Tory, K., Gnarra, J. R., Yao, M., Duh, F.-M. C., Orcutt, M. L., Stackhouse, T. M., Kuzmin, I., Modi, W. S., Geil, L., et al. (1993) · Science · doi:10.1126/science.8493574 · Cited by 2,971
Purification and Characterization of Hypoxia-inducible Factor 1
Wang, G. L., & Semenza, G. L. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.3.1230 · Cited by 2,094
HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression
Keith, B., Johnson, R. S., & Simon, M. C. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3183 · Cited by 1,693
Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer
Zhang, Z., Lee, J. C., Lin, L., Olivas, V., Au, V., LaFramboise, T., Abdel-Rahman, M., Wang, X., Levine, A. D., Rho, J. K., et al. (2012) · Nature Genetics · doi:10.1038/ng.2330 · Cited by 1,224

Show all 45 references

Sorted by citations

Items 101–200 of 271

C-Met as a Key Factor Responsible for Sustaining Undifferentiated Phenotype and Therapy Resistance in Renal Carcinomas
Marona, P., Górka, J., Kotlinowski, J., Majka, M., Jura, J., & Miękus, K. (2019) · Cells · doi:10.3390/cells8030272 · Cited by 35
The Immunotherapy Landscape in Renal Cell Carcinoma
Brown, L. C., Desai, K. B., Zhang, T., & Ornstein, M. C. (2020) · BioDrugs · doi:10.1007/s40259-020-00449-4 · Cited by 34
Targeting MERTK and AXL in EGFR Mutant Non-Small Cell Lung Cancer
Yan, D., Earp, H. S., DeRyckere, D., & Graham, D. K. (2021) · Cancers · doi:10.3390/cancers13225639 · Cited by 35
Hypoxia signaling and metastatic progression
Schito, L., & Rey-Keim, S. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.11.001 · Cited by 35
AXL is a potential therapeutic target in dedifferentiated and pleomorphic liposarcomas
May, C. D., Garnett, J., Ma, X., Landers, S. M., Ingram, D. R., Demicco, E. G., Sannaa, G. A. A., Vu, T., Han, L., Zhang, Y., et al. (2015) · BMC Cancer · doi:10.1186/s12885-015-1916-3 · Cited by 34
Novel Axl-driven signaling pathway and molecular signature characterize high-grade ovarian cancer patients with poor clinical outcome
Rea, K., Pinciroli, P., Sensi, M., Alciato, F., Bisarò, B., Lozneanu, L., Raspagliesi, F., Centritto, F., Cabodi, S., Defilippi, P., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5087 · Cited by 34
KDM4B/JMJD2B is a p53 target gene that modulates the amplitude of p53 response after DNA damage
Castellini, L., Moon, E. J., Razorenova, O. V., Krieg, A. J., von Eyben, R., & Giaccia, A. J. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw1281 · Cited by 35
Self-citation
Inhibition of the Receptor Tyrosine Kinase AXL Restores Paclitaxel Chemosensitivity in Uterine Serous Cancer
Palisoul, M. L., Quinn, J. M., Schepers, E. J., Hagemann, I. S., Guo, L., Reger, K., Hagemann, A. R., McCourt, C. K., Thaker, P. H., Powell, M. A., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0587 · Cited by 33
Self-citation
IDH2 reprograms mitochondrial dynamics in cancer through a HIF‐1α‐regulated pseudohypoxic state
Wang, Y., Agarwal, E., Bertolini, I., Ghosh, J. C., Seo, J. H., & Altieri, D. C. (2019) · The FASEB Journal · doi:10.1096/fj.201901366r · Cited by 34
AXL Is a Key Factor for Cell Plasticity and Promotes Metastasis in Pancreatic Cancer
Du, W., Phinney, N. Z., Huang, H., Wang, Z., Westcott, J. M., Toombs, J. E., Zhang, Y., Beg, M. S., Wilkie, T. M., Lorens, J. B., et al. (2021) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-20-0860 · Cited by 36
Practical management of adverse events associated with cabozantinib treatment in patients with renal-cell carcinoma
Gerendash, B., & Creel, P. A. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s145295 · Cited by 33
Dynamics of Axl Receptor Shedding in Hepatocellular Carcinoma and Its Implication for Theranostics
Holstein, E., Binder, M., & Mikulits, W. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19124111 · Cited by 33
AXL modulates extracellular matrix protein expression and is essential for invasion and metastasis in endometrial cancer
Divine, L. M., Nguyen, M. R., Meller, E. H., Desai, R. A., Arif, B., Rankin, E. B., Bligard, K. H., Meyerson, C., Hagemann, I. S., Massad, M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12637 · Cited by 32
Self-citation
Multifaceted Interplay between Hormones, Growth Factors and Hypoxia in the Tumor Microenvironment
Lappano, R., Todd, L. A., Stanic, M., Cai, Q., Maggiolini, M., Marincola, F., & Pietrobon, V. (2022) · Cancers · doi:10.3390/cancers14030539 · Cited by 32
Does Axl have potential as a therapeutic target in pancreatic cancer?
Du, W., & Brekken, R. A. (2018) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2018.1527315 · Cited by 32
Targeting of the AXL receptor tyrosine kinase by small molecule inhibitor leads to AXL cell surface accumulation by impairing the ubiquitin-dependent receptor degradation
Lauter, M., Weber, A., & Torka, R. (2019) · Cell Communication and Signaling · doi:10.1186/s12964-019-0377-8 · Cited by 32
Expression of tyrosine kinase receptor AXL is associated with worse outcome of metastatic renal cell carcinomas treated with sunitinib
Zucca, L. E. R., Morini, M. A., Oliveira, R. J. D. S., Scapulatempo‐Neto, C., de Lima, M. A., Ribeiro, G., Viana, C. R., Cárcano, F. M., & Reis, R. M. (2017) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2017.09.003 · Cited by 31
Normalization of TAM post-receptor signaling reveals a cell invasive signature for Axl tyrosine kinase
Kimani, S. G., Kumar, S., Davra, V., Chang, Y., Kasikara, C., Geng, K., Tsou, W., Wang, S., Hoque, M., Boháč, A., et al. (2016) · Cell Communication and Signaling · doi:10.1186/s12964-016-0142-1 · Cited by 30
Travelling under pressure - hypoxia and shear stress in the metastatic journey
Ildız, E. S., Gvozdenovic, A., Kovacs, W. J., & Aceto, N. (2023) · Clinical & Experimental Metastasis · doi:10.1007/s10585-023-10224-8 · Cited by 31
Investigational MET inhibitors to treat Renal cell carcinoma
Nandagopal, L., Sonpavde, G., & Agarwal, N. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1673366 · Cited by 29
AXL activates YAP through the EGFR–LATS1/2 axis and confers resistance to EGFR-targeted drugs in head and neck squamous cell carcinoma
Okamoto, K., Ando, T., Izumi, H., Kobayashi, S. S., Shintani, T., Gutkind, J. S., Yanamoto, S., Miyauchi, M., & Kajiya, M. (2023) · Oncogene · doi:10.1038/s41388-023-02810-7 · Cited by 28
Gas6/AXL Alleviates Hepatic Ischemia/Reperfusion Injury by Inhibiting Ferroptosis via the PI3K/AKT Pathway
Zhan, M., Deng, L., Yao, L., Wang, W., Zhang, R., Xu, Y., Wang, Z., Yan, Q., Fang, Q., Du, J., et al. (2024) · Transplantation · doi:10.1097/tp.0000000000005036 · Cited by 27
Cabozantinib in the treatment of advanced renal cell carcinoma: clinical trial evidence and experience
Ruiz-Morales, J. M., & Heng, D. Y. C. (2016) · Therapeutic Advances in Urology · doi:10.1177/1756287216663073 · Cited by 27
p5RHH nanoparticle-mediated delivery of AXL siRNA inhibits metastasis of ovarian and uterine cancer cells in mouse xenografts
Mills, K. A., Quinn, J. M., Roach, S. T., Palisoul, M. L., Nguyen, M. R., Noia, H. M., Guo, L., Fazal, J. A., Mutch, D. G., Wickline, S. A., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-41122-3 · Cited by 27
Self-citation
Interplay between receptor tyrosine kinases and hypoxia signaling in cancer
Glück, A. A., Aebersold, D. M., Zimmer, Y., & Medová, M. (2015) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2015.02.018 · Cited by 26
AXL as a modulator of sunitinib response in glioblastoma cell lines
Martinho, O., Zucca, L. E. R., & Reis, R. M. (2015) · Experimental Cell Research · doi:10.1016/j.yexcr.2015.01.009 · Cited by 27
MerTK inhibition by RXDX-106 in MerTK activated gastric cancer cell lines
Kim, J. E., Kim, Y., Li, G., Kim, S. T., Kim, K., Park, S. H., Park, J. O., Park, Y. S., Lim, H. Y., Lee, H., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.22394 · Cited by 26
A novel human anti‐AXL monoclonal antibody attenuates tumour cell migration
Duan, Y., Luo, L., Qiao, C., Li, X., Wang, J., Liu, H., Zhou, T., Shen, B., Lv, M., & Feng, J. (2019) · Scandinavian Journal of Immunology · doi:10.1111/sji.12777 · Cited by 26
Discovery of pyrrolo[2,3-d]pyrimidine derivatives as potent Axl inhibitors: Design, synthesis and biological evaluation
Xu, D., Sun, D., Wang, W., Peng, X., Zhan, Z., Ji, Y., Shen, Y., Geng, M., Ai, J., & Duan, W. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113497 · Cited by 27
Immunological role of TAM receptors in the cancer microenvironment
Gadiyar, V., Patel, G., & Davra, V. (2020) · International review of cytology · doi:10.1016/bs.ircmb.2020.09.011 · Cited by 27
AXL/CDCP1/SRC axis confers acquired resistance to osimertinib in lung cancer
Murakami, Y., Kusakabe, D., Watari, K., Kawahara, A., Azuma, K., Akiba, J., Taniguchi, M., Kuwano, M., & Ono, M. (2022) · Scientific Reports · doi:10.1038/s41598-022-12995-8 · Cited by 25
Emerging Targets in Clear Cell Renal Cell Carcinoma
Chen, Y., Rini, B. I., & Beckermann, K. E. (2022) · Cancers · doi:10.3390/cancers14194843 · Cited by 25
Cabozantinib for the treatment of renal cell carcinoma
Escudier, B. J., Lougheed, J. C., & Albiges, L. K. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1258059 · Cited by 25
Treatment of Advanced Renal Cell Carcinoma Patients with Cabozantinib, an Oral Multityrosine Kinase Inhibitor of MET, AXL and VEGF Receptors
Desai, A., & Small, E. J. (2019) · Future Oncology · doi:10.2217/fon-2019-0021 · Cited by 26
Emerging innovative treatment strategies for advanced clear cell renal cell carcinoma
Choi, S. H., Chen, Y., Panian, J. A., Yuen, K., & McKay, R. R. (2024) · The Oncologist · doi:10.1093/oncolo/oyae276 · Cited by 27
Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma and its association with PD-L1 expression
Lalani, A. A., Gray, K. P., Albiges, L. K., Callea, M., Pignon, J., Pal, S., Gupta, M., Bhatt, R. S., McDermott, D. F., Atkins, M. B., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.21952 · Cited by 24
Targeting AXL and the DNA Damage Response Pathway as a Novel Therapeutic Strategy in Melanoma
Karlsen, K. F., McFadden, E., Omar, N., Haugen, M. H., Øy, G. F., Ryder, T., Gullestad, H. P., Hermann, R., Mælandsmo, G. M., & Flørenes, V. A. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0290 · Cited by 24
Safety and Efficacy of Cabozantinib for Metastatic Nonclear Renal Cell Carcinoma
Prisciandaro, M., Ratta, R., Massari, F., Fornarini, G., Caponnetto, S., Iacovelli, R., Giorgi, U. D., Facchini, G., Scagliarini, S., Sabbatini, R., et al. (2018) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000478 · Cited by 24
For robust big data analyses: a collection of 150 important pro-metastatic genes
Mei, Y., Yang, J.-P., & Qian, C.-N. (2017) · 癌症：英文版 · doi:10.1186/s40880-016-0178-z · Cited by 23
A review on the role of GAS6 and GAS6-AS1 in the carcinogenesis
Ghafouri‐Fard, S., Khoshbakht, T., Taheri, M. N., & Mokhtari, M. (2021) · Pathology - Research and Practice · doi:10.1016/j.prp.2021.153596 · Cited by 23
Target‐Mediated Drug Disposition Pharmacokinetic/Pharmacodynamic Model‐Informed Dose Selection for the First‐in‐Human Study of AVB‐S6‐500
Bonifacio, L., Dodds, M., Prohaska, D., Moss, A. M., Giaccia, A. J., Tabibiazar, R., & McIntyre, G. (2019) · Clinical and Translational Science · doi:10.1111/cts.12706 · Cited by 23
Self-citation
Integrated Omics Analysis of Non-Small-Cell Lung Cancer Cells Harboring the EGFR C797S Mutation Reveals the Potential of AXL as a Novel Therapeutic Target in TKI-Resistant Lung Cancer
Wang, T., Wu, C., Huang, K., Leu, Y., Yang, S., Chen, C., & Chen, C. (2020) · Cancers · doi:10.3390/cancers13010111 · Cited by 23
Current and Emerging Therapeutic Targets for Metastatic Renal Cell Carcinoma
Zarrabi, K. K., & Wu, S. (2018) · Current Oncology Reports · doi:10.1007/s11912-018-0684-z · Cited by 22
Targeting angiogenesis in metastatic renal cell carcinoma
Canino, C., Perrone, L., Bosco, E., Saltalamacchia, G., Mosca, A., Rizzo, M., & Porta, C. (2019) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2019.1574574 · Cited by 22
Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma
Powles, T. B., Choueiri, T. K., Motzer, R. J., Jonasch, E. W., Pal, S. K., Tannir, N. M., Signoretti, S., Kaldate, R., Scheffold, C., Wang, E. W., et al. (2021) · BMC Cancer · doi:10.1186/s12885-021-08630-w · Cited by 21
Cabozantinib in the treatment of advanced renal cell carcinoma: design, development, and potential place in the therapy
Procopio, G., Grassi, P., Verzoni, E., Ratta, R., Mennitto, A., & de Braud, F. (2016) · Drug Design Development and Therapy · doi:10.2147/dddt.s104225 · Cited by 21
Axl and Mer Receptor Tyrosine Kinases: Distinct and Nonoverlapping Roles in Inflammation and Cancer?
Dransfield, I., & Farnworth, S. L. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-39406-0_5 · Cited by 22
MicroRNA-217: a therapeutic and diagnostic tumor marker
Hamidi, A. A., Zangoue, M., Kashani, D., Zangouei, A. S., Rahimi, H. R., Abbaszadegan, M. R., & Moghbeli, M. (2021) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2022.2017284 · Cited by 21
Gas6 expression is reduced in advanced breast cancers
Ibrahim, A. M., Gray, Z., Gomes, A. M., Myers, L., Behbod, F., & Machado, H. L. (2020) · npj Precision Oncology · doi:10.1038/s41698-020-0116-z · Cited by 20
Role of Nuclear Claudin-4 in Renal Cell Carcinoma
Owari, T., Sasaki, T., Fujii, K., Fujiwara‐Tani, R., Kishi, S., Mori, S., Mori, T., Goto, K., Kawahara, I., Nakai, Y., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218340 · Cited by 20
Oncofetal reprogramming in tumor development and progression: novel insights into cancer therapy
Cao, J., Zhang, Z., Zhou, L., Luo, M., Li, L., Li, B., Nice, E. C., He, W., Zheng, S., & Huang, C. (2023) · MedComm · doi:10.1002/mco2.427 · Cited by 19
Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma
Wu, Y., Chen, S., Yang, X., Sato, K., Lal, P., Wang, Y., Shinkle, A. T., Wendl, M. C., Primeau, T. M., Zhao, Y., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-23-0604 · Cited by 20
The Role of MicroRNAs upon Epithelial-to-Mesenchymal Transition in Inflammatory Bowel Disease
Boros, É., & Nagy, I. (2019) · Cells · doi:10.3390/cells8111461 · Cited by 21
TAMing resistance to multi-targeted kinase inhibitors through Axl and Met inhibition
Pinato, D. J., Chowdhury, S., & Stebbing, J. (2015) · Oncogene · doi:10.1038/onc.2015.374 · Cited by 20
Co-targeting JAK1/STAT6/GAS6/TAM signaling improves chemotherapy efficacy in Ewing sarcoma
Yu, L., Deng, Y., Wang, X., Santos, C., Davis, I. J., Earp, H. S., & Liu, P. (2024) · Nature Communications · doi:10.1038/s41467-024-49667-2 · Cited by 21
Targeting apoptosis in clear cell renal cell carcinoma
Kowalewski, A., Borowczak, J., Maniewski, M., Gostomczyk, K., Grzanka, D., & Szylberg, Ł. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116805 · Cited by 18
Cabozantinib inhibits AXL- and MET-dependent cancer cell migration induced by growth-arrest-specific 6 and hepatocyte growth factor
Hara, T., Kimura, A., Miyazaki, T., Tanaka, H., Morimoto, M., Nakai, K., & Soeda, J. (2020) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2020.100726 · Cited by 17
Sequencing Therapies for Metastatic Renal Cell Carcinoma
Dizman, N., ARSLAN, Z. E., Feng, M. I., & Pal, S. K. (2020) · Urologic Clinics of North America · doi:10.1016/j.ucl.2020.04.008 · Cited by 17
Intrinsic and Extrinsic Control of Hepatocellular Carcinoma by TAM Receptors
Hedrich, V., Breitenecker, K., Djerlek, L., Ortmayr, G., & Mikulits, W. (2021) · Cancers · doi:10.3390/cancers13215448 · Cited by 17
The Hypoxia–Long Noncoding RNA Interaction in Solid Cancers
Son, S. W., Yun, B. D., Song, M. G., Lee, J. K., Choi, S. Y., Kuh, H. J., & Park, J. K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147261 · Cited by 16
AXL/Gas6 signaling mechanisms in the hypothalamic-pituitary-gonadal axis
Mohammadzadeh, P., & Amberg, G. C. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1212104 · Cited by 15
Recent progress in the development of hypoxia-inducible factor 2α (HIF-2α) modulators: Inhibitors, agonists, and degraders (2009–2024)
Cheng, B., Ma, X.-S., Zhou, Y., Liu, J., Fei, X., Pan, W., Peng, X., Wang, W., & Chen, J. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116645 · Cited by 17
An epigenetic switch regulates the ontogeny of AXL-positive/EGFR-TKi-resistant cells by modulating miR-335 expression
Pal, D., Tepeš, P. Š., Lindsted, T., Ibarra, I., Lujambio, A., Sabinina, V. J., Şentürk, Ş., Miller, M. A., Korimerla, N., Huang, J., et al. (2021) · eLife · doi:10.7554/elife.66109 · Cited by 15
Dasatinib overcomes stroma-based resistance to the FLT3 inhibitor quizartinib using multiple mechanisms
Patel, A. B., Pomicter, A. D., Yan, D., Eiring, A. M., Antelope, O., Schumacher, J. A., Kelley, T. W., Tantravahi, S. K., Kovacsovics, T. J., Shami, P. J., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0858-1 · Cited by 17
The Role of Axl Receptor Tyrosine Kinase in Tumor Cell Plasticity and Therapy Resistance
Davidsen, K. T., Haaland, G. S., Lie, M. K., Lorens, J. B., & Engelsen, A. S. T. (2017) · Springer eBooks · doi:10.1007/978-3-319-39147-2_15 · Cited by 14
Qigesan reduces the motility of esophageal cancer cells via inhibiting Gas6/Axl and NF-κB expression
Kong, L., Wu, Z., Zhao, Y., Lu, X., Shi, H., Shugang, L., & Li, J. (2019) · Bioscience Reports · doi:10.1042/bsr20190850 · Cited by 14
Renal cell carcinoma: molecular characterization and evolving treatment paradigms
Ball, M. W., Singer, E. A., & Srinivasan, R. (2017) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000364 · Cited by 13
Targeting TOP2A in Ovarian Cancer: Biological and Clinical Implications
Borella, F., Fucina, S., Seminara, Y., Denti, P., Ferraioli, D., Bertero, L., Gallio, N., Cusato, J., Valabrega, G., Revelli, A., et al. (2024) · Current Oncology · doi:10.3390/curroncol31120594 · Cited by 13
Qigesan inhibits esophageal cancer cell invasion and migration by inhibiting Gas6/Axl-induced epithelial-mesenchymal transition
Kong, L., Lu, X., Chen, X., Wu, Y., Zhang, Y., Shi, H., & Li, J. (2020) · Aging · doi:10.18632/aging.103238 · Cited by 13
Targeting cyclin-dependent kinase 9 by a novel inhibitor enhances radiosensitization and identifies Axl as a novel downstream target in esophageal adenocarcinoma
Veeranki, O. L. M., Tong, Z., Dokey, R., Mejia, A., Zhang, J., Qiao, Y., Singh, P. K., Katkhuda, R., Mino, B., Tailor, R. C., et al. (2019) · Oncotarget · doi:10.18632/oncotarget.27095 · Cited by 13
Receptor Tyrosine Kinases in Osteosarcoma: 2019 Update
Greenfield, E. M., Collier, C. D., & Getty, P. J. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-43085-6_9 · Cited by 13
Promalignant effects of antiangiogenics in the tumor microenvironment
Peix, F., & Casanovas, O. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.03.003 · Cited by 12
Elevated Expression of AXL May Contribute to the Epithelial-to-Mesenchymal Transition in Inflammatory Bowel Disease Patients
Boros, É., Kellermayer, Z., Balogh, P., Strifler, G., Vörös, A., Sarlós, P., Vincze, Á., Varga, C., & Nagy, I. (2018) · Mediators of Inflammation · doi:10.1155/2018/3241406 · Cited by 12
Royaume du Maroc
Benhima (1962) · Présence Africaine · doi:10.3917/presa.042.0147 · Cited by 13
AXL Tyrosine Kinases: A Growing Isoform Family That Promotes Cancer Pathogenesis
Gjerstad, M. E., Aehnlich, P., Gélébart, P., & McCormack, E. (2025) · Cancer Research · doi:10.1158/0008-5472.can-24-3841 · Cited by 12
Quantitative Tyrosine Phosphoproteome Profiling of AXL Receptor Tyrosine Kinase Signaling Network
Wu, X., Wang, L., Pearson, N. A., Renuse, S., Cheng, R., Liang, Y., Mun, D., Madugundu, A. K., Xu, Y., Gill, P. S., et al. (2021) · Cancers · doi:10.3390/cancers13164234 · Cited by 9
Gas6 in chronic liver disease—a novel blood-based biomarker for liver fibrosis
Staufer, K., Huber, H., Zessner‐Spitzenberg, J., Stauber, R. E., Finkenstedt, A., Bantel, H., Weiß, T. S., Huber, M., Starlinger, P. P., Gruenberger, T., et al. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01551-6 · Cited by 11
Self-citation
Gas6-Axl signaling in presence of Sunitinib is enhanced, diversified and sustained in renal tumor cells, resulting in tumor-progressive advantages
Gustafsson, A., Fritz, H. K. M., & Dahlbäck, B. (2017) · Experimental Cell Research · doi:10.1016/j.yexcr.2017.03.040 · Cited by 11
CDCP1 promotes compensatory renal growth by integrating Src and Met signaling
Kajiwara, K., Yamano, S., Aoki, K., Okuzaki, D., Matsumoto, K., & Okada, M. (2021) · Life Science Alliance · doi:10.26508/lsa.202000832 · Cited by 11
USP7 depletion potentiates HIF2α degradation and inhibits clear cell renal cell carcinoma progression
Tu, R., Ma, J., Chen, Y., Kang, Y., Ren, D., Cai, Z., Zhang, R., Pan, Y., Liu, Y., Da, Y., et al. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-07136-0 · Cited by 11
Activated AXL Protects Against Hepatic Ischemia-reperfusion Injury by Upregulating SOCS-1 Expression
Wang, Z., Deng, L., Yan, Q., Liu, F., Zhan, M., Qi, S., Fang, Q., Yao, L., Wang, W., Zhang, R., et al. (2022) · Transplantation · doi:10.1097/tp.0000000000004156 · Cited by 10
Proteolysis of TAM receptors in autoimmune diseases and cancer: what does it say to us?
Malikova, I., Worth, A., Aliyeva, D., Khassenova, M., Kriajevska, M. V., & Tulchinsky, E. M. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07480-9 · Cited by 10
Altered expression of AXL receptor tyrosine kinase in gastrointestinal cancers: a promising therapeutic target
Pidkovka, N. A., & Belkhiri, A. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1079041 · Cited by 9
Engineered AXL‑ECD‑Fc variants that abolish the AXL/Gas6 interaction suppress tumor cell migration
Duan, Y., Hu, B., Qiao, C., Luo, L., Li, X., Wang, J., Liu, H., Zhou, T., Shen, B., Lv, M., et al. (2019) · Oncology Letters · doi:10.3892/ol.2019.10255 · Cited by 9
Spatial and temporal patterns in the Mediterranean populations of Aristaeomorpha foliacea and Aristeus antennatus (Crustacea: Decapoda: Aristeidae) based on the MEDITS surveys
Guijarro, B., Bitetto, I., D’Onghia, G., Follesa, M. C., Kapiris, K., Mannini, A., Marković, O., Micallef, R., Ragonese, S., Skarvelis, K., et al. (2019) · Scientia Marina · doi:10.3989/scimar.05012.04a · Cited by 9
Differential effects of HIF2α antagonist and HIF2α silencing in renal cancer and sensitivity to repurposed drugs
Arnaiz, E., Miar, A., Bridges, E., Prasad, N., Hatch, S. B., Ebner, D. V., Lawrie, C. H., & Harris, A. L. (2021) · BMC Cancer · doi:10.1186/s12885-021-08616-8 · Cited by 11
The Elongin BC Complex Negatively Regulates AXL and Marks a Differentiated Phenotype in Melanoma
Schieven, S. M., Traets, J. J. H., Vliet, A. V., Baalen, M. V., Song, J., Guimaraes, M. D. S., Kuilman, T., & Peeper, D. S. (2023) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-22-0648 · Cited by 10
Synergism of the receptor tyrosine kinase Axl with ErbB receptors mediates resistance to regorafenib in hepatocellular carcinoma
Breitenecker, K., Hedrich, V., Pupp, F., Chen, D., Řezníčková, E., Ortmayr, G., Huber, H., Weber, G., Balcar, L., Pinter, M., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1238883 · Cited by 8
Molecular analysis of alternative transcripts of equine AXL receptor tyrosine kinase gene
Park, J.-W., Song, K., Kim, N.-Y., Choi, J., Hong, S. A., Oh, J. H., Kim, S. W., Lee, J. H., Park, T. S., Kim, J., et al. (2017) · Asian-Australasian Journal of Animal Sciences · doi:10.5713/ajas.17.0409 · Cited by 8
Targeting TAM to Tame Pancreatic Cancer
von Itzstein, M. S., Burke, M., Brekken, R. A., Aguilera, T. A., Zeh, H. J., & Beg, M. S. (2020) · Targeted Oncology · doi:10.1007/s11523-020-00751-9 · Cited by 9
Biparatopic single-domain antibodies against Axl achieve ultra-high affinity through intramolecular engagement
Henry, K. A., Nguyen, T.-D., Baral, T. N., Hussack, G., Raphael, S., Arbabi‐Ghahroudi, M., Robert, A., Durocher, Y., Wu, C., Jaramillo, M., et al. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2021.05.030 · Cited by 8
Transcatheter arterial embolization combined with hypoxia-replicative oncolytic adenovirus perfusion enhances the therapeutic effect of hepatic carcinoma
Zhang, H., Xiong, F., Qian, K., Liu, Y., Liang, B., Xiong, B., Yang, F., & Zheng, C. (2019) · Cancer Management and Research · doi:10.2147/cmar.s189208 · Cited by 8
Inhibition of AXL and VEGF-A Has Improved Therapeutic Efficacy in Uterine Serous Cancer
Toboni, M. D., Lomonosova, E. E., Bruce, S. F., Tankou, J., Mullen, M. M., Schab, A. M., Oplt, A., Noia, H. M., Wilke, D., Kuroki, L. M., et al. (2021) · Cancers · doi:10.3390/cancers13235877 · Cited by 7
Self-citation
MicroRNA Expression in Clear Cell Renal Cell Carcinoma Cell Lines and Tumor Biopsies: Potential Therapeutic Targets
Swearson, S., Rataan, A. O., Eliason, S. L., Amendt, B. A., Zakharia, Y., Salem, A. K., Ho, T. H., & Rustum, Y. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23105604 · Cited by 7
Final efficacy and safety results and biomarker analysis of a phase 2 study of cabozantinib in Japanese patients with advanced renal cell carcinoma
Nakaigawa, N., Tomita, Y., Tamada, S., Tatsugami, K., Osawa, T., Oya, M., Kanayama, H., Miura, Y., Sassa, N., Nishimura, K., et al. (2023) · International Journal of Clinical Oncology · doi:10.1007/s10147-022-02283-w · Cited by 7
Real-world efficacy and safety of cabozantinib following immune checkpoint inhibitor failure in Japanese patients with advanced renal cell carcinoma
Ishihara, H., Nemoto, Y., Tachibana, H., Fukuda, H., Yoshida, K., Kobayashi, H., Iizuka, J., Hashimoto, Y., Kondo, T., & Takagi, T. (2023) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyad087 · Cited by 7
RNASE4 promotes malignant progression and chemoresistance in hypoxic glioblastoma via activation of AXL/AKT and NF-κB/cIAPs signaling pathways
Lee, H. (2024) · American Journal of Cancer Research · doi:10.62347/udbj5986 · Cited by 6
Targeting AXL can effectively overcome c-Met-induced therapeutic resistance in renal cancer and promote tumor cell death through increased oxidative stress
Sabarwal, A., Machaalani, M., Rawat, L., Wedel, J., Tabasum, S., Sasamoto, Y., Buerger, F., Ascione, J., Eid, M., Semaan, K., et al. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217984 · Cited by 6
Biological Issues with Cabozantinib in Bone Metastatic Renal Cell Carcinoma and Castration-Resistant Prostate Cancer
Nunno, V. D., Cimadamore, A., Santoni, M., Scarpelli, M., Fiorentino, M., Ciccarese, C., Iacovelli, R., Liang Cheng, C., Antonio Lopez-beltran, B., Massari, F., et al. (2018) · Future Oncology · doi:10.2217/fon-2018-0158 · Cited by 6
SQ1274, a novel microtubule inhibitor, inhibits ovarian and uterine cancer cell growth
Mills, K. A., Roach, S. T., Quinn, J. M., Guo, L., Beck-Noia, H., Lomonosova, E. E., Ilivicky, A. R., Starks, C. M., Lawrence, J. A., Hagemann, A. R., et al. (2018) · Gynecologic Oncology · doi:10.1016/j.ygyno.2018.08.008 · Cited by 6
Self-citation

Authors: Rankin, E. B., Fuh, K. C., Castellini, L., Viswanathan, K., Finger, E. C., Diep, A. N., LaGory, E. L., Kariolis, M. S., Chan, A., Lindgren, D., Axelson, H., Miao, Y. R., Krieg, A. J., & Giaccia, A. J.
Affiliations: Stanford Medicine (US)
Lund University (SE)
University of Kansas Medical Center (US)
ORCID: Rankin, Erinn B.
Fuh, Katherine C.
Castellini, Laura
Viswanathan, Kartik
Diep, Anh N.
LaGory, Edward L.
Kariolis, Mihalis S.
Lindgren, David
Axelson, Håkan
Miao, Yu R.
Krieg, Adam J.
Giaccia, Amato J.
Venue: Proceedings of the National Academy of Sciences
Publisher: National Academy of Sciences
Published: 2014-09-03
Volume: 111
Issue: 37
Pages: 13373-13378
ISSN: 0027-8424 (ISSN-L)
1091-6490
DOI: 10.1073/pnas.1404848111
PMC: PMC4169907
OpenAlex: W2079075723
Cited by: 269
References: 45
Citations by year: 2026: 8 · 2025: 13 · 2024: 17 · 2023: 29 · 2022: 20 · 2021: 32 · 2020: 26 · 2019: 28 · 2018: 21 · 2017: 34 · 2016: 23 · 2015: 16 · 2014: 1
FWCI: 19.79
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Proceedings of the National Academy of Sciences (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Lund University Publications (Lund University) (submittedVersion)
Funders: National Institutes of Health (CA67166)
U.S. Public Health Service (ARO65403)
National Cancer Institute (P01CA067166, CA088480, R37CA088480, R01CA088480, CA 67166, T32CA121940, T32CA009302)
Army Research Office
Topics: Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
Keywords: Gas6/Axl signaling, HIF-1, HIF-2, clear cell renal cell carcinoma, renal metastasis, MET oncogene, tumor invasion, therapeutic target
MeSH terms: Proto-Oncogene Mas, Axl Receptor Tyrosine Kinase, Endothelial PAS Domain-Containing Protein 1, Growth Arrest-Specific Protein 6, Carcinoma, Renal Cell, Enzyme Activation, Humans, Kidney Neoplasms, Models, Biological, Neoplasm Invasiveness, Phenotype, Proto-Oncogene Proteins, Signal Transduction, Cell Hypoxia, Treatment Outcome, Hepatocyte Growth Factor, src-Family Kinases, Proto-Oncogene Proteins c-met, Receptor Protein-Tyrosine Kinases, Intercellular Signaling Peptides and Proteins, Cell Line, Tumor, Basic Helix-Loop-Helix Proteins, Basic Helix-Loop-Helix Transcription Factors, Von Hippel-Lindau Tumor Suppressor Protein, Hypoxia-Inducible Factor 1, alpha Subunit

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks